Review: Peroxisome Proliferator-Activated Receptor-γ and Its Role in the Development and Treatment of Diabetes

Yazar: Leff, Todd, Mathews, Suresh T., Camp, Heidi S.
Baskı/Yayın Bilgisi 2004

Thiazolidinediones and insulin resistance: Peroxisome proliferatoractivated receptor γ activation stimulates expression of the CAP gene

Yazar: Ribon, Vered, Johnson, John H., Camp, Heidi S., Saltiel, Alan R.
Baskı/Yayın Bilgisi 1998

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection

Yazar: Mohamed, Mohamed‐Eslam F., Klünder, Ben, Camp, Heidi S., Othman, Ahmed A.
Yayımlandı Clin Pharmacol Ther (2019)

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib

Yazar: Mohamed, Mohamed‐Eslam F., Beck, Denise, Camp, Heidi S., Othman, Ahmed A.
Yayımlandı J Clin Pharmacol (2019)

PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis

Yazar: Ren, Delin, Collingwood, Trevor N., Rebar, Edward J., Wolffe, Alan P., Camp, Heidi S.
Baskı/Yayın Bilgisi 2002

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: resul...

Yazar: Strand, Vibeke, Pope, Janet, Tundia, Namita, Friedman, Alan, Camp, Heidi S., Pangan, Aileen, Ganguli, Arijit, Fuldeore, Mahesh, Goldschmidt, Debbie, Schiff, Michael
Yayımlandı Arthritis Res Ther (2019)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumat...

Yazar: Strand, Vibeke, Pope, Janet, Tundia, Namita, Friedman, Alan, Camp, Heidi S., Pangan, Aileen, Ganguli, Arijit, Fuldeore, Mahesh, Goldschmidt, Debbie, Schiff, Michael
Yayımlandı Arthritis Res Ther (2020)

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy

Yazar: Kremer, Joel M., Emery, Paul, Camp, Heidi S., Friedman, Alan, Wang, Li, Othman, Ahmed A., Khan, Nasser, Pangan, Aileen L., Jungerwirth, Steven, Keystone, Edward C.
Yayımlandı Arthritis Rheumatol (2016)

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Yazar: Genovese, Mark C., Smolen, Josef S., Weinblatt, Michael E., Burmester, Gerd R., Meerwein, Sebastian, Camp, Heidi S., Wang, Li, Othman, Ahmed A., Khan, Nasser, Pangan, Aileen L., Jungerwirth, Steven
Yayımlandı Arthritis Rheumatol (2016)

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

Yazar: Parmentier, Julie M., Voss, Jeff, Graff, Candace, Schwartz, Annette, Argiriadi, Maria, Friedman, Michael, Camp, Heidi S., Padley, Robert J., George, Jonathan S., Hyland, Deborah, Rosebraugh, Matthew, Wishart, Neil, Olson, Lisa, Long, Andrew J.
Yayımlandı BMC Rheumatol (2018)

Reduced heart size and increased myocardial fuel substrate oxidation in ACC2 mutant mice

Yazar: Essop, M. Faadiel, Camp, Heidi S., Choi, Cheol Soo, Sharma, Saumya, Fryer, Ryan M., Reinhart, Glenn A., Guthrie, Patrick H., Bentebibel, Assia, Gu, Zeiwei, Shulman, Gerald I., Taegtmeyer, Heinrich, Wakil, Salih J., Abu-Elheiga, Lutfi
Baskı/Yayın Bilgisi 2008